Vimarsana
Biggest News Aggregation in the World

Page 30 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19 - Vimarsana News

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and...

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Begins Construction of New Project in Omsk - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Begins Construction of New Project in Omsk

Investegate announcements from Etalon Group PLC, Etalon Begins Construction of New Project in Omsk

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC - Vimarsana News

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC 6th indication for toripalimab submitted in China GlobeNewswire December 10, 2021 SHANGHAI, China, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated...

Junshi Biosciences Announces NMPA Accepted supplemental New - Vimarsana News

Junshi Biosciences Announces NMPA Accepted supplemental New

6th indication for toripalimab submitted in China...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC